fluorodopa f 18 has been researched along with Nerve Degeneration in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwarz, J | 1 |
| Aquilonius, SM; Hartvig, PG; Långström, B; Tedroff, J | 1 |
| Degueldre, C; Franck, G; Garraux, G; Laureys, S; Lemaire, C; Peigneux, P; Salmon, E | 1 |
| Aebischer, P; Bloch, J; Brown, WD; Carvey, P; Chen, EY; Chu, Y; Déglon, N; Emborg, ME; Hantraye, P; Holden, JE; Kordower, JH; Leventhal, L; Ling, Z; Ma, SY; McBride, J; Palfi, S; Pyzalski, R; Roitberg, BZ; Taylor, MD; Trono, D | 1 |
| Broussolle, E; Guillouet, S; Thobois, S | 1 |
3 review(s) available for fluorodopa f 18 and Nerve Degeneration
| Article | Year |
|---|---|
[Nuclear medicine imaging in patients with Parkinson's syndrome: an update].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Energy Metabolism; Fluorodeoxyglucose F18; Genetic Predisposition to Disease; Humans; Nerve Degeneration; Neurons; Parkinson Disease; Parkinsonian Disorders; Positron-Emission Tomography; Receptors, Dopamine; Regional Blood Flow; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2010 |
Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration.
Topics: Animals; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Neostriatum; Nerve Degeneration; Substantia Nigra; Tomography, Emission-Computed | 1996 |
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Basal Ganglia; Brain Tissue Transplantation; Cell Transplantation; Cerebrovascular Circulation; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine Agonists; Electric Stimulation Therapy; Fetal Tissue Transplantation; Forecasting; Genetic Predisposition to Disease; Humans; Iatrogenic Disease; Imagination; Ligands; Mesencephalon; Motor Activity; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Radiopharmaceuticals; Rats; Receptors, Dopamine; Risk; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tremor | 2001 |
2 other study(ies) available for fluorodopa f 18 and Nerve Degeneration
| Article | Year |
|---|---|
Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration.
Topics: Aged; Basal Ganglia; Brain Diseases; Cerebral Cortex; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Nerve Degeneration; Parkinson Disease; Radiopharmaceuticals; Reference Values; Tissue Distribution; Tomography, Emission-Computed | 1999 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Lentivirus; Macaca mulatta; Neostriatum; Nerve Degeneration; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Parkinson Disease; Parkinsonian Disorders; Psychomotor Performance; Substantia Nigra; Tyrosine 3-Monooxygenase | 2000 |